ArticleScientific reports2025
PNPLA3 I148M variant is the main driver of weight gain after hepatitis C cure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in a Patient with Phelan-McDermid Syndrome.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BMI increase is commonly described in patients after chronic hepatitis C (HCV) cure with direct-acting antivirals. The aims of our study were to confirm the BMI increase compared with a population control group and to search for the allelic association between BMI increase and PNPLA3 gene I148M variant (G allele) carriage. We compared the BMI increase in 230 patients (HCV group) 3 years after the end of anti-HCV treatment with a group of 640 healthy subjects (controls) within the same period. The median BMI increase in the HCV group was 0.39 (range - 6.5-11.8), 0.70 in controls (-6.3 - 14.0); the difference was not significant (p = 0.95). However, the HCV subgroups showed significant difference according to PNPLA3 genotype: CC 0.0 (-6.5-8.7) vs. CG + GG 0.94 (-4.2-11.8), p = 0.0045, in contrast to the subgroups of controls: CC 0.7 (-5.1-13.7) vs. CG + GG 0.7 (-0.3-14.90), p = 0.86. BMI increase in the HCV subgroup CC + CG was significantly higher than in the entire control group (p = 0.035), whereas the HCV subgroup CC did not differ from controls (p = 0.07). The BMI increase was associated with PNPLA3 G allele carriage in the allelic model and the multivariate analysis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.